A Single-arm Interventional Phase IV, Post-authorisation Study Evaluating the Safety of Pediatric Patients With Transfusional Hemosiderosis Treated With Deferasirox Crushed Film Coated Tablets
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 17 Jul 2019
Price : $35 *
At a glance
- Drugs Deferasirox (Primary)
- Indications Haemosiderosis
- Focus Adverse reactions
- Acronyms MIMAS
- Sponsors Novartis Pharmaceuticals
- 11 Jul 2019 Status changed from recruiting to active, no longer recruiting.
- 29 Jun 2019 Planned End Date changed from 14 Nov 2019 to 30 Dec 2019.
- 28 May 2019 Planned End Date changed from 21 Jan 2020 to 14 Nov 2019.